OTC switch: change of legal status from prescription to non-prescription
An OTC switch reclassifies a medicine from prescription-only to non-prescription supply, decided by the authority that granted the authorisation.
Also known as: Rx-to-OTC switch, change of legal status, reclassification, prescription to non-prescription switch
4 min readUpdated
Reviewed by Gosia Luksza, CEO at Regunaut
At a glance
- Legal basis
- Articles 70 to 74a, Directive 2001/83/EC
- Test
- None of the prescription criteria in Article 71 applies
- Decided by
- Each Member State for national products; the Commission for centralised ones
- Incentive
- One year of protection for significant new data (Article 74a)
How it works
When an authorisation is granted, Article 70 of Directive 2001/83/EC requires the authority to classify the product as subject to medical prescription or not. Article 71 lists the reasons for prescription status: the product is likely to present a danger, directly or indirectly, if used without medical supervision, even when used correctly; it is frequently and to a very wide extent used incorrectly, with a likely danger to health as a result; it contains substances whose activity or adverse reactions need further investigation; or it is normally prescribed for parenteral administration. Under Article 72 a product that meets none of these criteria is not subject to prescription. Article 71(4) lets the authority waive prescription status having regard to the maximum single dose, the maximum daily dose, the strength, the pharmaceutical form, certain types of packaging or other circumstances of use.
A switch applies those criteria to a product that is already authorised. Article 74 requires authorities to re-examine the classification when new facts are brought to their attention, and in practice the holder applies for the change with evidence that the product can be used safely without a prescriber: post-marketing safety data, experience from countries where it is already sold without prescription, the consequences of misuse, overdose and delayed diagnosis, and a pack size, strength, indication and leaflet designed for self-selection. The Commission's guideline on changing the classification for the supply of a medicinal product for human use describes the data expected.
Legal status is one of the few parts of an authorisation that national procedures do not harmonise. For nationally authorised products, including those from mutual recognition and decentralised procedures, each Member State decides the classification for its own territory, so the same product can be non-prescription in one country and prescription-only in the next, and a switch is filed country by country under national rules. For centrally authorised products the classification is part of the Commission decision, and the switch is filed with EMA as a variation, in most cases a Type II variation. Many Member States also have sub-categories below the Directive, such as pharmacy-only supply or general sale, that differ widely.
Article 74a offers an incentive. Where a change of classification has been authorised on the basis of significant pre-clinical tests or clinical trials, the authority may not refer to the results of those tests or trials when examining an application by another applicant or holder for a change of classification of the same substance for one year after the first change was authorised.
What goes wrong
A switch dossier that argues from the safety of the molecule and ignores the Article 71 question of use without supervision; an indication that consumers cannot recognise for themselves; pack sizes and leaflets carried over from the prescription product; assuming that approval in one Member State carries over to another; claiming the Article 74a year for data that are not significant new tests or trials; and forgetting the downstream changes, since non-prescription status alters the advertising rules, pricing and reimbursement, the distribution channels and, in most cases, whether the pack carries the safety features of the Falsified Medicines Directive.
Timing
There is no dedicated EU timetable for a switch. One filed as a Type II variation follows the 60-day assessment, with clock-stops for supplementary information; national procedures follow national rules and timelines. Where the switch rests on significant new tests or trials, the one year of protection under Article 74a runs from the authorisation of the first change.
What the 2026 EU pharma package changes
Under the new pharma package (not yet in force), the classification rules gain new prescription-only cases: antimicrobials become subject to prescription, with a possible national waiver for topical use, and prescription status can be required as an environmental risk mitigation measure; see antimicrobial changes and prescription for environmental reasons.
OTC switch: common questions
What is an Rx-to-OTC switch?
It is the reclassification of an authorised medicine from prescription-only to non-prescription supply. The holder applies to the authority with evidence that the product no longer meets the prescription criteria in Article 71 of Directive 2001/83/EC, usually for a defined indication, strength and pack size suited to self-medication.
Who decides whether a medicine is prescription-only in the EU?
The authority that grants the authorisation. For nationally authorised products, including those from mutual recognition and decentralised procedures, each Member State classifies the product for its own territory, so legal status can differ between countries. For centrally authorised products the classification is set in the Commission decision following EMA's assessment.
Is there exclusivity for an OTC switch?
A limited one. Under Article 74a of Directive 2001/83/EC, where a change of classification was authorised on the basis of significant pre-clinical tests or clinical trials, the authority may not refer to those results when examining another company's application to switch the same substance for one year after the first change was authorised.